Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Parallel Group Study to Evaluate Efficacy and Safety of Lasmiditan Compared to Placebo in the Acute Treatment of Migraine

NCT04218162 is registered in ClinicalTrials.gov with IlDong Pharmaceutical Co Ltd as lead sponsor.

NCT NCT04218162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04218162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Parallel Group Study to Evaluate Efficacy and Safety of Lasmiditan Compared to Placebo in the Acute Treatment of Migraine
Lead sponsor
IlDong Pharmaceutical Co Ltd
Phase
Phase 3
Overall status
Completed
Start date
March 24, 2020
Completion date
October 30, 2020
Enrollment
294 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute migraine